Truro

Researchers are evaluating the safety, reactogenicity, and immune response of a vaccine called monovalent mRNA-1982 designed to prevent Lyme disease in healthy adults aged 18 to 70 years. This is a Phase 2 randomized, observer-blind, dose-finding, placebo-controlled clinical study focused on determining the best dose and monitoring reactions to the vaccine. Participants will receive either the mRNA-1982 vaccine or a placebo, both given as injections. The study is designed to compare these two groups to assess the vaccine's safety and immune effects. The research includes careful monitoring of local and systemic reactions after the injection, as well as longer-term safety observations. During the study, participants will be monitored for adverse reactions from the day of injection up to 7 days for local and systemic reactions, 28 days for unsolicited adverse events, and up to 21 months for medically attended and serious adverse events. Safety, reactogenicity, and immunogenicity are the main outcomes measured throughout the study period. Participants will undergo medical evaluations including medical history and physical exams at screening to ensure eligibility and safety.

Researchers are evaluating the effects and safety of AZD6793 tablets in adults aged 40 years and older who have moderate to very severe chronic obstructive pulmonary disease (COPD). This is a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study involving approximately 1160 participants at around 400 sites worldwide. The study aims to compare three different doses of AZD6793 against placebo tablets over 24 weeks to assess how well the treatment works and its safety profile in this population. Participants will be randomly assigned to one of four groups receiving either one of three doses of AZD6793 or a placebo in equal proportions. The treatment involves oral administration of AZD6793 tablets or placebo tablets daily for 24 weeks. The study is designed with parallel groups and includes careful dose-ranging to evaluate different levels of the investigational drug. During the study, participants will be monitored for the annualized rate of moderate or severe COPD exacerbations from baseline up to 24 weeks. Assessments include lung function tests such as pre- and post-bronchodilator FEV1/FVC ratios, symptom questionnaires like the COPD Assessment Test (CAT), and documentation of COPD exacerbation history. Safety will be continually evaluated through clinical assessments and laboratory tests throughout the treatment period.

This research aims to improve the use of Prison Needle Exchange Programs (PNEPs) in Canadian federal prisons, focusing on people who inject drugs while incarcerated. The study involves nine federal prisons, including five women's prisons where more individuals report injection drug use. The goal is to increase program adoption and sustainability by identifying what helps and hinders participation and implementing strategies based on evidence. The study uses a step-wedge design over 24 months, with nine prisons divided into three groups that receive the intervention at staggered intervals every six months. The intervention involves the Network for the Improvement of Addiction Treatment (NIATx) model, which uses expert coaching and quality improvement tools aimed specifically at behavioral healthcare settings to enhance access and retention. After the intervention period, there is an additional 12-month phase to assess how well the program is sustained. Participants include all people incarcerated at the study sites during the intervention period. Researchers will observe changes in PNEP uptake throughout the study and monitor the effectiveness of the NIATx strategy in improving program engagement. The study also assesses sustainability of the needle exchange programs after the intervention ends, with no exclusions at the participant level since the intervention is applied site-wide.